Recombinant Cynomolgus/Rhesus NKp30 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10947-NK

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10947-NK-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

XP_005553602.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all NKp30/NCR3 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived NKp30/NCR3 protein
Cynomolgus Monkey NKp30/NCR3
(Leu19-Gly137)
Accession # XP_005553602.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu19 and Ala18

Predicted Molecular Mass

40 kDa

SDS-PAGE

50-65 kDa, under reducing condtions

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human B7-H6 His-tag Protein (Catalog # 9309-B7) is immobilized at 0.5 μg/mL (100 μL/well), the concentration of Recombinant Cynomolgus Monkey/Rhesus Macaque NKp30/NCR3 Fc Chimera (Catalog # 10947-NK) that produces 50% of the optimal binding response is 4.00-24.0 ng/mL.

Scientific Data Images for Recombinant Cynomolgus/Rhesus NKp30 Fc Chimera Protein, CF

Recombinant Cynomolgus Monkey/Rhesus Macaque NKp30/NCR3 Fc Chimera Protein Binding Activity.

When Recombinant Human B7-H6 His-tag Protein (9309-B7) is immobilized at 0.5 μg/mL (100 μL/well), the concentration of Recombinant Cynomolgus Monkey/Rhesus Macaque NKp30/NCR3 Fc Chimera (Catalog # 10947-NK) that produces 50% of the optimal binding response is 4.00-24.0 ng/mL.

Recombinant Cynomolgus Monkey/Rhesus Macaque NKp30/NCR3 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Cynomolgus Monkey/Rhesus Macaque NKp30/NCR3 Fc Chimera (Catalog # 10947-NK) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 50-65 kDa and 100-130 kDa, respectively.

Formulation, Preparation and Storage

10947-NK
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: NKp30/NCR3

NKp30, also termed Natural cytotoxicity receptor 3 (NCR3), along with NKp44 and NKp46, constitute a group of receptors termed "Natural Cytotoxicity Receptors" (1). These receptors play a major role in triggering NK-mediated killing of most tumor cell lines. Mature NKp30 consists of an extracellular domain (ECD) with a V‑type Ig-like fold, a single transmembrane region and a short cytoplasmic domain (2). A charged residue in the transmembrane domain of NKp30 is responsible for association with the tyrosine-based activating motif (ITAM)‑bearing accessory protein CD3 zeta (2). The ECD of cynomologus NKp30 shares 93% amino acid sequence identity with the ECD of human NKp30. In human, several NKp30 isoforms arising from alternative splicing are known to exist (3). NKp30 is expressed on both resting and activated NK cells of the CD56dim, CD16+ subset and account for ~85% of NK cells found in peripheral blood and spleen (4). While NKp30 is absent from the CD56bright, CD16- subset that constitutes the majority of NK cells in lymph node and tonsil, its expression is up-regulated in these cells upon IL-2 activation (4). Studies with neutralizing antibodies reveal that NKp30 is partially responsible for triggering lytic activity against several tumor cell types and that it is the main receptor responsible for NK-mediated lysis of immature dendritic cells (2, 5). The B7 family member B7-H6, a tumor cell ligand, has been identified as activating NKp30 (6). Additionally, soluble galectin-3 released from tumor cells was found to bind NKp30 thereby inhibiting NKp30-mediated cytotoxicity (7).

References

  1. Moretta, L. and A. Moretta (2004) EMBO J. 23:255.
  2. Pende, D. et al. (1999) J. Exp. Med. 190:1505.
  3. Pinheiro, P.H. et al. (2020) Br J Pharmacol 177:4563.
  4. Ferlazzo, G. et al. (2004) J. Immunol. 172:1455.
  5. Ferlazzo, G. et al. (2002) J. Exp. Med. 195:343.
  6. Brandt, C.S. et al. (2009) J Exp Med. 206:1495.
  7. Kellner, C. et al. (2012) J Immunol. 189:5037.

Alternate Names

CD337, NCR3

Entrez Gene IDs

259197 (Human); 294251 (Rat); 102133932 (Cynomolgus Monkey)

Gene Symbol

NCR3

UniProt

XP_005553602.1

Additional NKp30/NCR3 Products

Product Documents for Recombinant Cynomolgus/Rhesus NKp30 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Cynomolgus/Rhesus NKp30 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.